Latest News
Arcturus Therapeutics and Thermo Fisher enter strategic collaboration on ARCT-032 development
2 July 2026 - Messenger RNA medicines company Arcturus Therapeutics Holdings Inc (Nasdaq:ARCT) announced on Thursday that it has entered into a strategic collaboration with Thermo Fisher Scientific Inc (NYSE:TMO) to support Phase 3 development and po...
United Therapeutics acquires Thymmune Therapeutics to expand regenerative cell therapy pipeline
2 July 2026 - Biotechnology company United Therapeutics Corporation (Nasdaq:UTHR) announced on Thursday that it has acquired Thymmune Therapeutics, a privately held, preclinical stage biotechnology company focused on regenerative thymic cell therapie...
Genentech reports positive Phase III results for divarasib in KRAS G12C lung cancer
2 July 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), on Thursday reported positive Phase III results from the Krascendo 1 trial evaluating investigational KRAS G12C inhibitor divarasib in patients ...
Alligator Bioscience reports first patient dosed in early-stage breast cancer study
2 July 2026 - Swedish biotechnology company Alligator Bioscience AB (STO:ATORX) reported on Thursday that the first patient has been dosed in an investigator-initiated trial evaluating intratumoural administration of its lead CD40 agonist, mitazalima...
Neurocrine Biosciences initiates crinecerfont Phase 2 study in young children with classic CAH
2 July 2026 - Biopharmaceutical company Neurocrine Biosciences Inc (Nasdaq:NBIX) announced on Wednesday the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 years with...